Abstract:Khaled S Allemailem, 1 Mohammed A Alsahli, 1 Ahmad Almatroudi, 1 Faris Alrumaihi, 1 Waleed Al Abdulmonem, 2 Amira A Moawad, 3 Wanian M Alwanian, 1 Nahlah Makki Almansour, 4 Arshad Husain Rahmani, 1 Amjad Ali Khan 5 1 Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia; 2 Department of Pathology, College of Medicine, Qassim University, Buraydah, Saudi Arabia; 3 Friedrich-Loeffler-Institut, Institute of Bacterial Infections and Zoonoses, Jena, Germany; 4 Department of Biology, College of Science, University of Hafr Al Batin, Hafr Al Batin, Saudi Arabia; 5 Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia Correspondence: Amjad Ali Khan, Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Buraydah, 51452, Saudi Arabia, Tel +966-16-3800050 Ext. 15445, Fax +966-16-3801628, Email The recent developments in the study of clustered regularly interspaced short palindromic repeats/associated protein 9 (CRISPR/Cas9) system have revolutionized the art of genome-editing and its applications for cellular differentiation and immune response behavior. This technology has further helped in understanding the mysteries of cancer progression and possible designing of novel antitumor immunotherapies. CRISPR/Cas9-based genome-editing is now often used to engineer universal T-cells, equipped with recombinant T-cell receptor (TCR) or chimeric antigen receptor (CAR). In addition, this technology is used in cytokine stimulation, antibody designing, natural killer (NK) cell transfer, and to overcome immune checkpoints. The innovative potential of CRISPR/Cas9 in preparing the building blocks of adoptive cell transfer (ACT) immunotherapy has opened a new window of antitumor immunotherapy and some of them have gained FDA approval. The manipulation of immunogenetic regulators has opened a new interface for designing, implementation and interpretation of CRISPR/Cas9-based screening in immuno-oncology. Several cancers like lymphoma, melanoma, lung, and liver malignancies have been treated with this strategy, once thought to be impossible. The safe and efficient delivery of CRISPR/Cas9 system within the immune cells for the genome-editing strategy is a challenging task which needs to be sorted out for efficient immunotherapy. Several targeting approaches like virus-mediated, electroporation, microinjection and nanoformulation-based methods have been used, but each procedure offers some limitations. Here, we elaborate the recent updates of cancer management through immunotherapy in partnership with CRISPR/Cas9 technology. Further, some innovative methods of targeting this genome-editing system within the immune system cells for reprogramming them, as a novel strategy of anticancer immunotherapy is elaborated. In addition, future prospects and clinical trials are also discussed. Keywords: CRISPR/Cas9, tumor microenvironment, immune response, molecular targeted therapy, cancer immunotherapy, nanotechnology, clinical study Cancer is well characterized by genomic instability resulting in structural alterations that build up with tumor progression. 1,2 A subpopulation of undifferentiated cancer cells, known as cancer stem cells (CSCs) are found within the tumor bulk. These cells are responsible for cancer initiation, recurrence and show therapeutic resistance and these cells have a potential role in immune surveillance evasion. Recent literature reveals the deeper interplay between CSCs and immune cells within tumor microenvironment (TME), as surprisingly, some major immune cells have a pivotal role in driving the expansion of CSCs. 3 The immune system recognizes the cancer and is poised to eliminate it, but sometimes the immune system is held in check by some inhibitory receptors and ligands. Recent advances in molecular targeted therapy as a novel treatment modality have revolutionized cancer management strategy and taken it to new heights. Different approaches of immunotherapy like immune checkpoint inhibitors (ICIs) and adoptive cell transfer (ACT) have led to satisfying clinical outcomes. However, their efficacies vary and these novel strategies are still very expensive and only a subset of cancer patients have benefited from them. 4 The immune surveillance function of different adaptive and innate immune cells within the TME are suppressed by multiple mechanisms. 5,6 A continuous selective pressure exerted by the host immune response in context of cancer, often results in tumor variants being skilled in surveillance evasion and enable the tumor cells to survive. Some of the known -Abstract Truncated-

CRISPR-engineered T cells in patients with refractory cancer

Abstract CT133: A Phase I Trial of PD-1 Deficient Engineered T Cells with CRISPR/Cas9 in Patients with Advanced Non-Small Cell Lung Cancer with PD-L1 Expression

Therapeutic potential of CRISPR/Cas9 gene editing in engineered T‐cell therapy

Therapeutic potential of CRISPR/CAS9 genome modification in T cell-based immunotherapy of cancer

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells

Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management

Abstract LB357: CRISPR-Cas9 targeting of somatic mutations selectively kills cancer cells

CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy

CRISPR-Cas gene knockouts to optimize engineered T cells for cancer immunotherapy

Exploiting the CRISPR‐Cas9 gene‐editing system for human cancers and immunotherapy

CRISPR/Cas9-Mediated Genome Editing in Cancer Therapy

Genome Editing in Engineered T Cells for Cancer Immunotherapy

Abstract 5: Cytosine base editor ameliorates the safety profile of TCR edited T cells for the adoptive cell therapy of gastrointestinal tumors

Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment

A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies

Safety and Feasibility of CRISPR-edited T Cells in Patients with Refractory Non-Small-cell Lung Cancer

Engineered Nanomaterials to Potentiate CRISPR/Cas9 Gene Editing for Cancer Therapy

Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease

Progress in the application of gene editing technology in cancer treatmentstaking CRISPR as an example

Generating universal anti-CD19 CAR T cells with a defined memory phenotype by CRISPR/Cas9 editing and safety evaluation of the transcriptome